Zevra Therapeutics Q3 2024 Earnings Report

Zevra Therapeutics EPS Results

• Actual EPS: -$0.69
• Consensus EPS: -$0.44
• Beat/Miss: Missed by -$0.25
• One Year Ago EPS: -$0.40

Zevra Therapeutics Revenue Results

• Actual Revenue: $3.70 million
• Expected Revenue: $5.04 million
• Beat/Miss: Missed by -$1.34 million
• YoY Revenue Growth: N/A

Zevra Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/12/2024
• Time: After Market Closes

Zevra Therapeutics (NASDAQ:ZVRA) discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.